Rosemarie Tully Appointed COO of Neuromod Devices Limited

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

Today Dublin based Neuromod Devices Limited announced the appointment of Rosemarie Tully as the new Chief Operating Officer (COO). Ms. Tully most recently held the role of Chief Business Officer, responsible for business development, corporate, and commercial strategy.

In addition to her current responsibilities for corporate development and strategy, Ms. Tully will now assume responsibility for all of Neuromod’s operating activities, including manufacturing, supply chain, regulatory, quality, and compliance functions. Ms. Tully will continue to report to Dr. Ross O’Neill, Chief Executive Officer of Neuromod.

As COO, Ms. Tully will play a key role in supporting Neuromod’s accelerated growth phase as it transitions from a research and development organization to a large-scale manufacturing organization, supporting the commercialization of the Company’s tinnitus treatment device, Lenire®. As COO, Ms. Tully’s key short-term focus will be scaling up manufacturing capacity of the Lenire® device to meet anticipated European demand; and implementing regulatory strategy required to support market entry into the United States.

Commenting on the announcement, Dr. Ross O Neill, CEO of Neuromod Devices said: “I am delighted to announce Rosemarie’s appointment as Chief Operating Officer. Rosemarie’s broad skill set and extensive international experience in senior leadership roles in the Pharma sector have been crucial to the development of Neuromod, since she joined the company in 2018. Rosemarie has also delivered key commercial initiatives like the successful launch of our Lenire® brand in Ireland and Germany. As COO she will continue to support myself and our newly appointed Chief Commercial Officer, Florian Elsäßer as the roll-out of our commercial strategy accelerates in key markets”.

Ms. Tully is a registered pharmacist, with more than 20 years of industry experience including senior roles in corporate development and strategy at Sigmoid Pharma (now Sublimity Therapeutics), Elan Corporation (now Perrigo), as well as strategy consulting experience at McKinsey & Company. Ms. Tully earned her BSc (Pharm) at Trinity College Dublin, Ireland, and an MBA from INSEAD, France.

 

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.